The Urine Albumin Creatinine Ratio (UACR) is an important indicator of kidney health that is used by doctors to assess the risk of developing chronic kidney disease (CKD). UACR is a measure of the amount of albumin, a protein, that is present in the urine, relative to the amount of creatinine, a waste product formed in the body. UACR is a useful tool for doctors to identify patients who are at risk for developing CKD, as well as those who may already be in the early stages of the disease.
UACR is a simple test that measures the amount of albumin and creatinine in a person's urine. Albumin is a protein that is normally found in the blood, but can be found in higher concentrations in the urine when the kidneys are not functioning properly. Creatinine is a waste product formed in the body and is normally excreted through the urine. UACR is measured by dividing the amount of albumin present in the urine (measured in milligrams per gram of creatinine) by the amount of creatinine present in the urine (measured in milligrams per gram of creatinine). The result is expressed as a ratio.
UACR is used to detect early signs of kidney damage, as well as to monitor the progression of CKD. UACR can be used to identify patients who are at risk for developing CKD, as well as those who may already be in the early stages of the disease. UACR can also be used to assess the effectiveness of treatments, such as medications or lifestyle changes, that are used to slow the progression of CKD. UACR is also used to monitor patients who have already been diagnosed with CKD to ensure that their kidney function is not deteriorating further.
The normal range for UACR is 0-30 mg/g. A UACR of 30 mg/g or higher is considered abnormal and may indicate the presence of kidney disease. It is important to note that a UACR of 30 mg/g or higher does not necessarily mean that a person has CKD. UACR can be elevated due to other factors, such as dehydration, infection, or certain medications. Therefore, it is important to consult with a doctor to determine the cause of an elevated UACR.
UACR testing is recommended for anyone who is at risk for developing CKD, including those with diabetes, hypertension, or a family history of CKD. Additionally, UACR testing is recommended for anyone who is already diagnosed with CKD, to monitor for any changes in kidney function.
The Urine Albumin Creatinine Ratio (UACR) is an important indicator of kidney health that is used by doctors to assess the risk of developing chronic kidney disease (CKD). UACR is a measure of the amount of albumin, a protein, that is present in the urine, relative to the amount of creatinine, a waste product formed in the body. UACR is a useful tool for doctors to identify patients who are at risk for developing CKD, as well as those who may already be in the early stages of the disease. UACR testing is recommended for anyone who is at risk for developing CKD, including those with diabetes, hypertension, or a family history of CKD. Additionally, UACR testing is recommended for anyone who is already diagnosed with CKD, to monitor for any changes in kidney function.
1.
The use of biomarkers in the treatment of breast lumps is at a crossroads.
2.
According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.
3.
How Do Younger People Fare With Stool Tests for CRC Screening?
4.
Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL
5.
Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer
1.
How Parvovirus B19 Affects Pregnant Women and Their Unborn Babies
2.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
3.
Introduction to Immune Thrombocytopenic Purpura
4.
Unveiling the Chadwick Sign: A Revolutionary New Tool for Detecting Early Signs of Cancer
5.
The Different Types of Cysts and Why They Occur: Insights from a Dermatologist
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment
2.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
3.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
5.
Navigating the Complexities of Ph Negative ALL - Part XII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation